Seres Therapeutics (NASDAQ:MCRB) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS
Seres Therapeutics (NASDAQ:MCRB) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS
Seres Therapeutics (NASDAQ:MCRB – Get Rating) issued its earnings results on Wednesday. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.04), reports. The firm had revenue of $3.44 million during the quarter, compared to analysts' expectations of $12.29 million. Seres Therapeutics had a negative net margin of 1,729.94% and a negative return on equity of 294.70%.
塞雷斯治疗公司(纳斯达克代码：MCRB-GET Rating)周三发布了财报。据报道，这家生物技术公司公布了本季度每股收益(0.49美元)，低于普遍预期的(0.45美元)和(0.04美元)。该公司当季营收为344万美元，高于分析师预期的1,229万美元。Seres治疗公司的净利润率为负1729.94%，净资产回报率为负294.70%。
Seres Therapeutics Trading Down 9.5 %
Seres治疗公司股价下跌9.5%
Shares of NASDAQ MCRB opened at $8.14 on Friday. Seres Therapeutics has a 12-month low of $2.50 and a 12-month high of $11.69. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 2.20. The firm's 50-day moving average is $6.61 and its two-hundred day moving average is $4.95.
上周五，纳斯达克MCRB的股价开盘报8.14美元。Seres Treateutics的12个月低点为2.50美元，12个月高位为11.69美元。该公司的速动比率为2.35，流动比率为2.35，债务权益比为2.20。该公司的50日移动均线切入位在6.61美元，200日移动均线切入位在4.95美元。
Analysts Set New Price Targets
分析师设定新的价格目标
A number of analysts recently commented on the stock. Chardan Capital decreased their price objective on shares of Seres Therapeutics from $16.00 to $12.00 in a report on Thursday, August 4th. StockNews.com raised shares of Seres Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, October 29th. Finally, Piper Sandler boosted their price objective on shares of Seres Therapeutics from $7.00 to $9.00 and gave the stock an "overweight" rating in a report on Wednesday, September 7th.
一些分析师最近对该股发表了评论。在8月4日星期四的一份报告中，Chardan Capital将Seres治疗公司的股票目标价从16.00美元下调至12.00美元。在10月29日星期六的一份报告中，StockNews.com将Seres Treateutics的股票评级从“卖出”上调至“持有”。最后，Piper Sandler将Seres治疗公司的股票目标价从7.00美元上调至9.00美元，并在9月7日星期三的一份报告中给予该股“增持”评级。
Insider Buying and Selling at Seres Therapeutics
Seres Treateutics的内幕买卖
Hedge Funds Weigh In On Seres Therapeutics
对冲基金入股Seres Treeutics
A number of institutional investors have recently modified their holdings of the company. FMR LLC raised its position in shares of Seres Therapeutics by 34.0% in the second quarter. FMR LLC now owns 18,601,212 shares of the biotechnology company's stock valued at $63,802,000 after buying an additional 4,723,347 shares during the last quarter. Federated Hermes Inc. increased its position in Seres Therapeutics by 124.5% during the second quarter. Federated Hermes Inc. now owns 17,982,256 shares of the biotechnology company's stock worth $61,679,000 after purchasing an additional 9,971,450 shares during the last quarter. BlackRock Inc. increased its position in Seres Therapeutics by 0.5% during the first quarter. BlackRock Inc. now owns 5,894,430 shares of the biotechnology company's stock worth $41,969,000 after purchasing an additional 31,739 shares during the last quarter. Vanguard Group Inc. increased its position in Seres Therapeutics by 8.4% during the first quarter. Vanguard Group Inc. now owns 5,066,930 shares of the biotechnology company's stock worth $36,076,000 after purchasing an additional 390,665 shares during the last quarter. Finally, State Street Corp increased its position in Seres Therapeutics by 1.3% during the first quarter. State Street Corp now owns 4,847,943 shares of the biotechnology company's stock worth $34,517,000 after purchasing an additional 62,354 shares during the last quarter. Institutional investors and hedge funds own 96.09% of the company's stock.
多家机构投资者最近调整了对该公司的持股。FMR LLC在第二季度将其在Seres Treateutics的股票头寸提高了34.0%。FMR LLC现在拥有这家生物技术公司18,601,212股，价值63,802,000美元，上个季度又购买了4,723,347股。联合爱马仕公司在第二季度将其在Seres治疗公司的地位增加了124.5%。联合爱马仕公司现在持有这家生物技术公司17,982,256股，价值61,679,000美元，在上个季度又购买了9,971,450股。贝莱德股份有限公司在第一季度将其在Seres治疗公司的头寸增加了0.5%。贝莱德股份有限公司目前持有这家生物技术公司5,894,430股股票，价值41,969,000美元，该公司在上个季度又购买了31,739股。第一季度，先锋集团在Seres Treateutics的股份增加了8.4%。先锋集团(Vanguard Group Inc.)在上个季度增持了390,665股后，现在持有这家生物技术公司5,066,930股股票，价值36,076,000美元。最后，道富集团在第一季度将其在Seres Treateutics的头寸增加了1.3%。道富集团目前持有这家生物技术公司4,847,943股股票，价值34,517,000美元，此前该公司在上个季度又购买了62,354股。机构投资者和对冲基金持有该公司96.09%的股票。
Seres Therapeutics Company Profile
Seres治疗公司简介
(Get Rating)
(获取评级)
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).
Seres治疗公司是一家微生物组治疗平台公司，致力于开发细菌联合体，这些细菌联合体旨在与宿主细胞和组织进行功能性相互作用，以治疗疾病。该公司的主要候选产品是SER-109，这是一种口服微生物群治疗候选药物，已经完成了治疗艰难梭菌感染(CDI)的第三阶段临床试验。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Seres Therapeutics (MCRB)
- MarketBeat: Week in Review 10/31-11/4
- Is Hershey's a Sweet Stock to Buy After a Post-Earnings Dip?
- Datadog Doesn't Belong In The Doghouse
- Nikola Shares Fall Even As EV Maker Beats Q3 Expectations
- Mixed Results Actually Bring More Optimism than Risk for AMD
- 免费获取StockNews.com关于Seres治疗(MCRB)的研究报告
- MarketBeat：回顾中的一周10/31-11/4
- 好时是一只在盈利后下跌后买入的甜蜜股票吗？
- Datadog不属于狗舍
- 尼古拉股价下跌，尽管电动汽车制造商第三季度业绩好于预期
- 喜忧参半的结果实际上给AMD带来的乐观情绪多于风险
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Seres治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Seres Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。